/
AEMD
$0.85-$0.02 (-2.85%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.1M
2M shares
52-week range
$0.78 – $27.40
0% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
13.56%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-4007.15
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $229.6K | $650.2K | $659.1K | $294.2K | $574.2K | $0 | $0 | $0 |
| Cost of revenue | $3.08B | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$2.85B | $650.2K | $659.1K | $294.2K | $574.2K | $0 | $0 | $0 |
| Gross margin | -1242674.4% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| R&D | $896.0K | $927.0K | $2.1M | $2.3M | $2.7M | $2.5M | $2.2M | $0 |
| Operating income | −$6.0M | −$5.9M | −$7.9M | −$10.4M | −$11.9M | −$12.6M | −$9.3M | −$7.3M |
| EBITDA | −$6.0M | −$5.9M | −$7.9M | −$10.3M | −$11.8M | −$11.8M | −$13.0M | −$6.8M |
| Net income | −$6.2M | −$6.4M | −$7.9M | −$10.4M | −$12.0M | −$12.2M | −$13.4M | −$7.2M |
| Net margin | -2697.9% | -980.3% | -1196.6% | -3540.9% | -2094.9% | — | — | — |
| EPS (diluted) | -512.70 | -186.70 | -65.20 | -70.60 | -58.60 | -48.60 | -85.80 | -10.61 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $0 | $-2.98 | $-4.57–$-1.39 | 1 |
| 2028 | $0 | $-1.80 | $-1.80–$-1.80 | 1 |
| 2029 | $0 | $-0.61 | $-0.61–$-0.61 | 1 |
| 2030 | $9M | $-0.30 | $-0.30–$-0.30 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$6.43
Price
$0.85
Implied upside
+658%
Peer comparison
AETHLON MEDICAL INC
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
www.aethlonmedical.com- Employees
- 9
- IPO / List date
- Nov 6, 1998
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds AEMD.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AEMD as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-10-20 | 1-for-10reverse |
| 2025-06-09 | 1-for-8reverse |
| 2023-10-05 | 1-for-10reverse |
| 2019-10-15 | 1-for-15reverse |
| 2015-04-14 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded AEMD yet.
